We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

Back to rankings

212 hedge funds and large institutions have $2.12B invested in Portola Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 92 increasing their positions, 46 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 92 | Existing positions reduced: 46

48% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 25

10% more capital invested

Capital invested by funds: $1.92B → $2.12B (+$201M)

5% more funds holding

Funds holding: 201 → 212 (+11)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

51% less call options, than puts

Call options by funds: $9.14M | Put options by funds: $18.6M

Holders
212
Holders Change
+11
Holders Change %
+5.47%
% of All Funds
4.65%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
37
Increased
92
Reduced
46
Closed
25
Calls
$9.14M
Puts
$18.6M
Net Calls
-$9.46M
Net Calls Change
-$2.74M

Top Buyers

Rank Fund Capital Flow
1
William Blair Investment Management
William Blair Investment Management
Illinois
+$52.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$34.1M
3
BlackRock
BlackRock
New York
+$25.1M
4
FLAM
First Light Asset Management
Minnesota
+$21.4M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$20.5M

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$17.4M
2
CCM
Cadian Capital Management
New York
-$11.9M
3
State Street
State Street
Massachusetts
-$11.8M
4
ACM
Asymmetry Capital Management
California
-$10.5M
5
Morgan Stanley
Morgan Stanley
New York
-$7.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
Macquarie Group
26
Macquarie Group
Australia
$14.7M +$1.22M +43,469 +9%
SAM
27
Sectoral Asset Management
Quebec, Canada
$14.7M -$4.91M -175,067 -24%
Invesco
28
Invesco
Georgia
$13.6M +$8.53M +303,955 +150%
EA
29
Emerald Advisers
Pennsylvania
$13.4M -$994K -35,406 -7%
PCM
30
Peregrine Capital Management
Minnesota
$12.8M +$348K +12,398 +3%
PC
31
Polar Capital
United Kingdom
$12.6M +$13.2M +471,362 New
EMFAT
32
Emerald Mutual Fund Advisers Trust
Pennsylvania
$12.6M -$195K -6,950 -1%
Charles Schwab
33
Charles Schwab
California
$11.6M +$1.05M +37,523 +10%
ECP
34
Elk Creek Partners
Colorado
$11.6M +$372K +13,236 +3%
RCM
35
RA Capital Management
Massachusetts
$11.5M +$12.1M +429,399 New
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$11.5M +$2.68M +95,491 +29%
TAM
37
Tocqueville Asset Management
New York
$10.7M -$1.97M -70,026 -15%
FIM
38
Fernwood Investment Management
Massachusetts
$10.1M -$171K -6,100 -2%
Two Sigma Advisers
39
Two Sigma Advisers
New York
$9.33M +$3.14M +111,700 +47%
CWG
40
C WorldWide Group
Denmark
$8.97M – – –
AI
41
Atom Investors
Texas
$8.6M +$2.12M +75,584 +31%
GC
42
Grace Capital
Massachusetts
$8.35M -$225K -8,000 -3%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$8.28M +$860K +30,650 +11%
N
44
Nuveen
North Carolina
$8.11M +$1.31M +46,662 +18%
Citadel Advisors
45
Citadel Advisors
Florida
$8.11M -$2.71M -96,689 -24%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$8.05M -$138K -4,902 -2%
Wells Fargo
47
Wells Fargo
California
$7.64M +$1.57M +55,880 +24%
Deutsche Bank
48
Deutsche Bank
Germany
$7.19M -$5.58M -198,802 -43%
SFM
49
Sphera Funds Management
Israel
$6.97M +$7.3M +260,000 New
MCM
50
Moore Capital Management
New York
$5.77M +$6.04M +215,209 New
1
2
3 4 5

PTLA Hedge Fund Activity: Q3 2019 in Review

212 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q3 2019, worth a combined $2.12B — up 10% from $1.92B a quarter earlier.

Buyers outnumbered sellers: 37 funds opened new PTLA positions and 25 closed out — a net gain of 12 holders — while 92 added to existing stakes and 46 trimmed.

The largest buyer was William Blair Investment Management, adding an estimated $52.3M. The largest seller was JP Morgan Chase, cutting an estimated $17.4M.

  • 212 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q3 2019, up from 201 in Q2 2019.
  • Funds reported $2.12B of Portola Pharmaceuticals, Inc. stock for Q3 2019, up 10% quarter-over-quarter.
  • 37 funds opened new Portola Pharmaceuticals, Inc. positions in Q3 2019 and 25 closed out, a net change of +12 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q3 2019 was William Blair Investment Management, an estimated $52.3M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q3 2019 was JP Morgan Chase, an estimated $17.4M sold.

Based on aggregated 13F filings for Q3 2019.